Trial Profile
A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels of Immunohistochemistry Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 24 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2005 New trial record.